EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 350 filers reported holding EXELIXIS INC in Q4 2020. The put-call ratio across all filers is 2.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,050 | -99.8% | 51 | -99.8% | 0.00% | -100.0% |
| Q3 2021 | $532,000 | -2.4% | 25,163 | +4.4% | 0.01% | -10.0% |
| Q1 2021 | $545,000 | +71.4% | 24,104 | +51.9% | 0.01% | +66.7% |
| Q4 2020 | $318,000 | -73.8% | 15,873 | -68.0% | 0.01% | -77.8% |
| Q3 2020 | $1,214,000 | -18.9% | 49,652 | -21.3% | 0.03% | -22.9% |
| Q2 2020 | $1,497,000 | -8.8% | 63,055 | -33.9% | 0.04% | -25.5% |
| Q1 2020 | $1,642,000 | -25.2% | 95,363 | -23.5% | 0.05% | -6.0% |
| Q4 2019 | $2,196,000 | -10.9% | 124,623 | -10.6% | 0.05% | -15.3% |
| Q3 2019 | $2,465,000 | -18.7% | 139,366 | -1.7% | 0.06% | -19.2% |
| Q2 2019 | $3,031,000 | +16.1% | 141,844 | +29.4% | 0.07% | +17.7% |
| Q1 2019 | $2,610,000 | +29.1% | 109,643 | +6.7% | 0.06% | +6.9% |
| Q4 2018 | $2,021,000 | +67.9% | 102,774 | +51.3% | 0.06% | +93.3% |
| Q3 2018 | $1,204,000 | -15.2% | 67,914 | +2.9% | 0.03% | -21.1% |
| Q2 2018 | $1,420,000 | +0.6% | 65,997 | +3.5% | 0.04% | -5.0% |
| Q1 2018 | $1,412,000 | – | 63,750 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |